Victoria Gray spent 34 years battling the debilitating pain of sickle cell disease. Then she volunteered to be the world's first "prototype" for a CRISPR therapy, based on technology invented at UC ...

CRISPR Therapeutics analysis: long-term upside despite volatility. Track Casgevy ramp, pipeline milestones & cash runway.

Innovative research into the gene-editing tool targets influenza’s ability to replicate—stopping it in its tracks.

A new CRISPR breakthrough shows scientists can turn genes back on without cutting DNA, by removing chemical tags that act ...

CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

The need to change regulations around gene-editing treatments was endorsed in November by the head of the US Food and Drug ...

Aurora Therapeutics, cofounded by Nobel Prize–winning scientist Jennifer Doudna, plans to use gene editing and a new FDA ...

Science and medicine are incredibly amazing. Thanks to modern science and medicine, we now have lifespans far beyond our Dark Age predecessors, living until ripe old age and enjoying the fruits of our ...

If I were to locate the moment AI slop broke through into popular consciousness, I’d pick the video of rabbits bouncing on a ...

Researchers at Utah State University revealed new details about CRISPR immune system defenses, such as Cas12a3 systems, that ...

Whales with a lot of money to spend have taken a noticeably bearish stance on CRISPR Therapeutics. Looking at options history for CRISPR Therapeutics (NASDAQ:CRSP) we detected 13 trades. If we ...

If you are wondering whether CRISPR Therapeutics at about US$53.84 is still priced attractively or already baking in a lot of ...